Table 1.
Characteristics of cases and controls at DCCT and EDIC study visits.
| Clinical parameters | DCCT | EDIC | ||||
|---|---|---|---|---|---|---|
|
Cases N = 34 |
Controls N = 51 |
P‐value* |
Cases N = 34 |
Controls N = 51 |
P‐value* | |
| EDIC/DCCT year visit** | 1 (0–3) | 1 (0–7) | 0.47 | 18 (8–26) | 16 (9–24) | 0.003 |
| Age (years) | 35 (14–41) | 36 (14–44) | 0.85 | 51 (25–62) | 51 (25–57) | 0.016 |
| Males % | 74 | 68 | 0.51 | 74 | 68 | 0.51 |
| Disease duration (months) | 61 (25–184) | 70 (26–210) | 0.29 | 276 (108–408) | 240 (132–408) | 0.028 |
| HbA1C (%) | 8.7 (6.0–15) | 8.0 (5–11) | 0.23 | 8.3 (5.5–12.7) | 8.0 (6.3–10.7) | 0.026 |
| SBP (mmHg) | 114 (90–138) | 116 (90–134) | 0.86 | 139 (104–173) | 133 (102–155) | 0.043 |
| DBP (mmHg) | 74 (60–90) | 74 (58–88) | 0.87 | 83 (56–102) | 80 (60–100) | 0.63 |
| eGFR (ml/min per 1.73 m2) | 119 (81–207) | 113 (88–148) | 0.86 | 76 ( 60–119) | 91 (62–120) | 0.02 |
| Intensive treatment (%) | 9 (35%) | 11 (32%) | 0.8 | 13 (38%) | 21 (41%) | 0.82 |
| Standard treatment (%) | 17 (65%) | 23 (68%) | 0.8 | 21 (62%) | 30 (59%) | 0.82 |
| RAS Blockers (%) | 0 | 0 | 68 | 31 | 0.002 | |
| Anti‐hypertensives (%) | 0 | 0 | 76 | 33 | <0.001 | |
Even though the group statistics are similar or identical, the p‐values are significant in some cases because comparisons are made within matched sets for the conditional logistic regression
*
P‐value as obtained per conditional regression analysis.
**
The DCCT year visit is the earliest visit in DCCT when the study sample was available.